Immunotherapy utilization in stage IIIA melanoma: less may be more.

ABSTRACT:

Background

Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for significant variation in prescribing patterns. This study aimed to characterize current immunotherapy practice variations and to compare patient outcomes for different prescribing practices in stage IIIA melanoma.

Study design

Patients with melanoma diagnosed from 2015-2019 that met American Joint Committee on Cancer 8th edition criteria for stage IIIA and underwent resection were identified in the National Cancer Database. Multiple imputation by chained equations replaced missing va

SUBMITTER: Frey AE 

PROVIDER: S-EPMC10876869 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature